The role of ryanodine receptor type 3 in a mouse model of Alzheimer disease

Channels

Volumn 8, Issue 3, 2014, Pages 230-242

  Liu, Jie ^a   Supnet, Charlene ^a   Sun, Suya ^a   Zhang, Hua ^a   Good, Levi ^a   Popugaeva, Elena ^b   Bezprozvanny, Ilya ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PETER THE GREAT ST PETERSBURG POLYTECHNIC UNIVERSITY   (Russian Federation)

Author keywords

Amyloid load; Arc; Caffeine; EEG; Ryanodine receptor; Spine morphology; Spontaneous activity

Indexed keywords

AMYLOID BETA PROTEIN; RYANODINE RECEPTOR;

ALZHEIMER DISEASE; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENETICS; HIPPOCAMPUS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MOUSE; NERVE CELL;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL;

EID: 84901341037     PISSN: 19336950     EISSN: 19336969     Source Type: Journal    
DOI: 10.4161/chan.27471     Document Type: Article

References (59)

1. Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 2008; 31:454-63; PMID:18675468; http://dx.doi.org/10.1016/j.tins.2008.06.005
2. Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med 2009; 15:89-100; PMID:19230774; http://dx.doi.org/10.1016/j.molmed.2009. 01.001
3. Supnet C, Bezprozvanny I. Neuronal calcium signaling, mitochondrial dysfunction, and Alzheimer's disease. J Alzheimers Dis 2010; 20(Suppl 2):S487-98; PMID:20413848
4. Supnet C, Bezprozvanny I. The dysregulation of intracellular calcium in Alzheimer disease. Cell Calcium 2010; 47:183-9; PMID:20080301; http://dx.doi.org/10.1016/j.ceca.2009.12.014
5. Popugaeva E, Supnet C, Bezprozvanny I. Presenilins, deranged calcium homeostasis, synaptic loss and dysfunction in Alzheimer's disease. Messenger 2012; 1:53-62; http://dx.doi.org/10.1166/msr.2012.1002
6. Bezprozvanny I, Hiesinger PR. The synaptic maintenance problem: membrane recycling, Ca2+ homeostasis and late onset degeneration. Mol Neurodegener 2013; 8:23; PMID:23829673; http://dx.doi.org/10.1186/1750-1326-8-23
7. Ito E, Oka K, Etcheberrigaray R, Nelson TJ, McPhie DL, Tofel-Grehl B, Gibson GE, Alkon DL. Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci U S A 1994; 91:534-8; PMID:8290560; http://dx.doi.org/10.1073/pnas.91.2.534
8. Stutzmann GE, Smith I, Caccamo A, Oddo S, Laferla FM, Parker I. Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci 2006; 26:5180-9; PMID:16687509; http://dx.doi.org/10.1523/JNEUROSCI.0739-06.2006
9. Kelliher M, Fastbom J, Cowburn RF, Bonkale W, Ohm TG, Ravid R, Sorrentino V, O'Neill C. Alterations in the ryanodine receptor calcium release channel correlate with Alzheimer's disease neurofibrillary and beta-amyloid pathologies. Neuroscience 1999; 92:499-513; PMID:10408600; http://dx.doi.org/10.1016/S0306- 4522(99)00042-1
10. Bruno AM, Huang JY, Bennett DA, Marr RA, Hastings ML, Stutzmann GE. Altered ryanodine receptor expression in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2012; 33:1001 e1-6.
11. Chan SL, Mayne M, Holden CP, Geiger JD, Mattson MP. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem 2000; 275:18195-200; PMID:10764737; http://dx.doi.org/10.1074/jbc.M000040200
12. Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I. Role of presenilins in neuronal calcium homeostasis. J Neurosci 2010; 30:8566-80; PMID:20573903; http://dx.doi.org/10.1523/JNEUROSCI.1554-10.2010
13. Supnet C, Grant J, Kong H, Westaway D, Mayne M. Amyloid-beta-(1-42) increases ryanodine receptor-3 expression and function in neurons of TgCRND8 mice. J Biol Chem 2006; 281:38440-7; PMID:17050533; http://dx.doi.org/10.1074/ jbc.M606736200
14. van de Vrede Y, Fossier P, Baux G, Joels M, Chameau P. Control of IsAHP in mouse hippocampus CA1 pyramidal neurons by RyR3-mediated calcium-induced calcium release. Pflugers Arch 2007; 455:297-308; PMID:17562071; http://dx.doi.org/10.1007/s00424-007-0277-4
15. Sah P, Faber ES. Channels underlying neuronal calcium-activated potassium currents. Prog Neurobiol 2002; 66:345-53; PMID:12015199; http://dx.doi.org/10. 1016/S0301-0082(02)00004-7
16. Reyes M, Stanton PK. Induction of hippocampal long-term depression requires release of Ca2+ from separate presynaptic and postsynaptic intracellular stores. J Neurosci 1996; 16:5951-60; PMID:8815877
17. Futatsugi A, Kato K, Ogura H, Li ST, Nagata E, Kuwajima G, Tanaka K, Itohara S, Mikoshiba K. Facilitation of NMDAR-independent LTP and spatial learning in mutant mice lacking ryanodine receptor type 3. Neuron 1999; 24:701-13; PMID:10595520; http://dx.doi.org/10.1016/S0896-6273(00)81123-X
18. Galeotti N, Quattrone A, Vivoli E, Norcini M, Bartolini A, Ghelardini C. Different involvement of type 1, 2, and 3 ryanodine receptors in memory processes. Learn Mem 2008; 15:315-23; PMID:18441289; http://dx.doi.org/10.1101/ lm.929008
19. Supnet C, Noonan C, Richard K, Bradley J, Mayne M. Up-regulation of the type 3 ryanodine receptor is neuroprotective in the TgCRND8 mouse model of Alzheimer's disease. J Neurochem 2010; 112:356-65; PMID:19903243; http://dx.doi.org/10.1111/j.1471-4159.2009.06487.x
20. Oulès B, Del Prete D, Greco B, Zhang X, Lauritzen I, Sevalle J, Moreno S, Paterlini-Bréchot P, Trebak M, Checler F, et al. Ryanodine receptor blockade reduces amyloid-β load and memory impairments in Tg2576 mouse model of Alzheimer disease. J Neurosci 2012; 32:11820-34; PMID:22915123; http://dx.doi.org/10.1523/JNEUROSCI.0875-12.2012
21. Peng J, Liang G, Inan S, Wu Z, Joseph DJ, Meng Q, Peng Y, Eckenhoff MF, Wei H. Dantrolene ameliorates cognitive decline and neuropathology in Alzheimer triple transgenic mice. Neurosci Lett 2012; 516:274-9; PMID:22516463; http://dx.doi.org/10.1016/j.neulet.2012.04.008
22. Chakroborty S, Briggs C, Miller MB, Goussakov I, Schneider C, Kim J, Wicks J, Richardson JC, Conklin V, Cameransi BG, et al. Stabilizing ER Ca2+ channel function as an early preventative strategy for Alzheimer's disease. PLoS One 2012; 7:e52056; PMID:23284867; http://dx.doi.org/10.1371/journal.pone. 0052056
23. Zhao X, Weisleder N, Han X, Pan Z, Parness J, Brotto M, Ma J. Azumolene inhibits a component of storeoperated calcium entry coupled to the skeletal muscle ryanodine receptor. J Biol Chem 2006; 281:33477-86; PMID:16945924; http://dx.doi.org/10.1074/jbc.M602306200
24. Giannini G, Conti A, Mammarella S, Scrobogna M, Sorrentino V. The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues. J Cell Biol 1995; 128:893-904; PMID:7876312; http://dx.doi.org/10.1083/jcb.128.5.893
25. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F. Dantrolene - a review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004; 59:364-73; PMID:15023108; http://dx.doi.org/10.1111/j.1365-2044.2004. 03658.x
26. Bertocchini F, Ovitt CE, Conti A, Barone V, Schöler HR, Bottinelli R, Reggiani C, Sorrentino V. Requirement for the ryanodine receptor type 3 for efficient contraction in neonatal skeletal muscles. EMBO J 1997; 16:6956-63; PMID:9384575; http://dx.doi.org/10.1093/emboj/16.23.6956
27. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jäggi F, Wolburg H, Gengler S, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006; 7:940-6; PMID:16906128; http://dx.doi.org/10.1038/sj.embor.7400784
28. Takeshima H, Komazaki S, Hirose K, Nishi M, Noda T, Iino M. Embryonic lethality and abnormal cardiac myocytes in mice lacking ryanodine receptor type 2. EMBO J 1998; 17:3309-16; PMID:9628868; http://dx.doi.org/10.1093/emboj/17.12. 3309
29. Lanner JT, Georgiou DK, Joshi AD, Hamilton SL. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Perspect Biol 2010; 2:a003996; PMID:20961976; http://dx.doi.org/10. 1101/cshperspect.a003996
30. Tang TS, Guo C, Wang H, Chen X, Bezprozvanny I. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. J Neurosci 2009; 29:1257-66; PMID:19193873; http://dx.doi.org/10.1523/JNEUROSCI.4411-08.2009
31. Kasumu AW, Liang X, Egorova P, Vorontsova D, Bezprozvanny I. Chronic suppression of inositol 1,4,5-triphosphate receptor-mediated calcium signaling in cerebellar purkinje cells alleviates pathological phenotype in spinocerebellar ataxia 2 mice. J Neurosci 2012; 32:12786-96; PMID:22973002; http://dx.doi.org/10.1523/JNEUROSCI.1643-12.2012
32. Balschun D, Wolfer DP, Bertocchini F, Barone V, Conti A, Zuschratter W, Missiaen L, Lipp HP, Frey JU, Sorrentino V. Deletion of the ryanodine receptor type 3 (RyR3) impairs forms of synaptic plasticity and spatial learning. EMBO J 1999; 18:5264-73; PMID:10508160; http://dx.doi.org/10.1093/emboj/18.19.5264
33. Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu GQ, Kreitzer A, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007; 55:697-711; PMID:17785178; http://dx.doi.org/10.1016/j.neuron.2007.07.025
34. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297:353-6; PMID:12130773; http://dx.doi.org/10.1126/science.1072994
35. Hyman BT. Amyloid-dependent and amyloidindependent stages of Alzheimer disease. Arch Neurol 2011; 68:1062-4; PMID:21482918; http://dx.doi.org/10.1001/ archneurol.2011.70
36. Kasai H, Matsuzaki M, Noguchi J, Yasumatsu N, Nakahara H. Structure-stability-function relationships of dendritic spines. Trends Neurosci 2003; 26:360-8; PMID:12850432; http://dx.doi.org/10.1016/S0166-2236(03)00162-0
37. Bourne JN, Harris KM. Balancing structure and function at hippocampal dendritic spines. Annu Rev Neurosci 2008; 31:47-67; PMID:18284372; http://dx.doi.org/10.1146/annurev.neuro.31.060407.125646
38. Bourne J, Harris KM. Do thin spines learn to be mushroom spines that remember? Curr Opin Neurobiol 2007; 17:381-6; PMID:17498943; http://dx.doi.org/10.1016/j.conb.2007.04.009
39. Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci 2011; 14:285-93; PMID:21346746; http://dx.doi.org/10.1038/nn.2741
40. Dickstein DL, Weaver CM, Luebke JI, Hof PR. Dendritic spine changes associated with normal aging. Neuroscience 2012; In press; PMID:23069756.
41. Luebke JI, Weaver CM, Rocher AB, Rodriguez A, Crimins JL, Dickstein DL, Wearne SL, Hof PR. Dendritic vulnerability in neurodegenerative disease: insights from analyses of cortical pyramidal neurons in transgenic mouse models. Brain Struct Funct 2010; 214:181-99; PMID:20177698; http://dx.doi.org/10.1007/ s00429-010-0244-2
42. Tackenberg C, Ghori A, Brandt R. Thin, stubby or mushroom: spine pathology in Alzheimer's disease. Curr Alzheimer Res 2009; 6:261-8; PMID:19519307; http://dx.doi.org/10.2174/156720509788486554
43. Tackenberg C, Brandt R. Divergent pathways mediate spine alterations and cell death induced by amyloidbeta, wild-type tau, and R406W tau. J Neurosci 2009; 29:14439-50; PMID:19923278; http://dx.doi.org/10.1523/JNEUROSCI.3590-09. 2009
44. Dumitriu D, Rodriguez A, Morrison JH. Highthroughput, detailed, cell-specific neuroanatomy of dendritic spines using microinjection and confocal microscopy. Nat Protoc 2011; 6:1391-411; PMID:21886104; http://dx.doi.org/10. 1038/nprot.2011.389
45. Rodriguez A, Ehlenberger DB, Dickstein DL, Hof PR, Wearne SL. Automated three-dimensional detection and shape classification of dendritic spines from fluorescence microscopy images. PLoS One 2008; 3:e1997.
46. Wegenast-Braun BM, Fulgencio Maisch A, Eicke D, Radde R, Herzig MC, Staufenbiel M, Jucker M, Calhoun ME. Independent effects of intra- and extracellular Abeta on learning-related gene expression. Am J Pathol 2009; 175:271-82; PMID:19556514; http://dx.doi.org/10.2353/ajpath.2009.090044
47. Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S, Malinow R. APP processing and synaptic function. Neuron 2003; 37:925-37; PMID:12670422; http://dx.doi.org/10.1016/S0896-6273(03)00124-7
48. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. Neuron 2005; 48:913-22; PMID:16364896; http://dx.doi.org/10.1016/j.neuron.2005.10.028
49. van Gelder BM, Buijsse B, Tijhuis M, Kalmijn S, Giampaoli S, Nissinen A, Kromhout D. Coffee consumption is inversely associated with cognitive decline in elderly European men: the FINE Study. Eur J Clin Nutr 2007; 61:226-32; PMID:16929246; http://dx.doi.org/10.1038/sj.ejcn.1602495
50. Ritchie K, Carrière I, de Mendonca A, Portet F, Dartigues JF, Rouaud O, Barberger-Gateau P, Ancelin ML. The neuroprotective effects of caffeine: a prospective population study (the Three City Study). Neurology 2007; 69:536-45; PMID:17679672; http://dx.doi.org/10.1212/01.wnl.0000266670.35219.0c
51. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis 2009; 16:85-91; PMID:19158424
52. Laitala VS, Kaprio J, Koskenvuo M, Räihä I, Rinne JO, Silventoinen K. Coffee drinking in middle age is not associated with cognitive performance in old age. Am J Clin Nutr 2009; 90:640-6; PMID:19587088; http://dx.doi.org/10.3945/ajcn.2009.27660
53. Cao C, Loewenstein DA, Lin X, Zhang C, Wang L, Duara R, Wu Y, Giannini A, Bai G, Cai J, et al. High Blood caffeine levels in MCI linked to lack of progression to dementia. J Alzheimers Dis 2012; 30:559-72; PMID:22430531
54. Cao C, Cirrito JR, Lin X, Wang L, Verges DK, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash GW, et al. Caffeine suppresses amyloidbeta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis 2009; 17:681-97; PMID:19581723
55. Arendash GW, Schleif W, Rezai-Zadeh K, Jackson EK, Zacharia LC, Cracchiolo JR, Shippy D, Tan J. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain betaamyloid production. Neuroscience 2006; 142:941-52; PMID:16938404; http://dx.doi.org/10.1016/j.neuroscience.2006. 07.021
56. Arendash GW, Mori T, Cao C, Mamcarz M, Runfeldt M, Dickson A, Rezai-Zadeh K, Tane J, Citron BA, Lin X, et al. Caffeine reverses cognitive impairment and decreases brain amyloid-beta levels in aged Alzheimer's disease mice. J Alzheimers Dis 2009; 17:661-80; PMID:19581722
57. Qosa H, Abuznait AH, Hill RA, Kaddoumi A. Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J Alzheimers Dis 2012; 31:151-65; PMID:22504320
58. Espinosa J, Rocha A, Nunes F, Costa MS, Schein V, Kazlauckas V, Kalinine E, Souza DO, Cunha RA, Porciúncula LO. Caffeine consumption prevents memory impairment, neuronal damage, and adenosine A2A receptors upregulation in the hippocampus of a rat model of sporadic dementia. J Alzheimers Dis 2013; 34:509-18; PMID:23241554
59. Shimizu H, Fukaya M, Yamasaki M, Watanabe M, Manabe T, Kamiya H. Use-dependent amplification of presynaptic Ca2+ signaling by axonal ryanodine receptors at the hippocampal mossy fiber synapse. Proc Natl Acad Sci U S A 2008; 105:11998-2003; PMID:18687898; http://dx.doi.org/10.1073/pnas.0802175105